DICERNA PHARMACEUTICALS INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) – marketscreener.com

Payments received from our collaboration partners during the three and nine months ended September 30, 2021 were as follows (amounts in thousands):
* Percentage change not meaningful
Payments received from our collaboration partners during the three and nine months ended September 30, 2020 were as follows (amounts in thousands):
Net cash provided by operating activities $ 68,353 $ 222,415 Net cash used in investing activities $ (49,840) $ (216,882) Net cash provided by financing activities $ 20,476 $ 48,400
$ 12 $ –
____________________________
——————————————————————————–
Table of Contents
© Edgar Online, source Glimpses

source